HB4019, titled “Gio’s Law,” would create a federal grant program within the Omnibus Crime Control and Safe Streets Act of 1968 to help states and local governments equip law enforcement agencies with epinephrine products and train officers to use them. The bill directs the Attorney General to award grants for purchasing epinephrine auto-injectors and other epinephrine delivery products, and for training state, local, and tribal officers to recognize anaphylaxis and administer epinephrine appropriately.
The bill also requires the Attorney General to develop or identify standardized training curricula within 180 days of enactment, and it conditions grant applications on a certification that officers authorized to administer epinephrine are protected from civil liability under state law. In addition, it authorizes $25 million annually for fiscal years 2026 through 2030, requires the Bureau of Justice Statistics to report annually on how often law enforcement administers epinephrine, and directs a public awareness campaign with HHS to educate the public about anaphylaxis and the role of first responders.
Impact
HB4019 would amend federal criminal justice grant law by adding a new part to Title I of the Omnibus Crime Control and Safe Streets Act of 1968. It would create a new funding stream for state, local, and tribal law enforcement agencies to purchase epinephrine products, train officers, and support public education and reporting. The bill would also indirectly affect state law by requiring a state attorney general certification that officers administering epinephrine are shielded from civil liability, which could encourage states to adopt or clarify Good Samaritan-style protections for law enforcement responders.
Sentiment
The available context shows little recorded debate or formal vote history, as the bill was only referred to the House Judiciary Committee. Based on the bill’s structure and bipartisan sponsorship, the measure appears to be framed as a public-safety and emergency-response bill rather than a partisan policy change. Its emphasis on lifesaving treatment for anaphylaxis and training for first responders suggests generally favorable intent, with the main policy focus on implementation and liability protection rather than ideological disagreement.
Contention
The most notable point of contention is likely the civil-liability certification requirement, because grant eligibility depends on whether state law protects officers who administer epinephrine from lawsuits. That could raise questions about state sovereignty, the adequacy of existing immunity laws, and whether jurisdictions without such protections would need to change their statutes to participate. Another possible issue is whether law enforcement should be equipped and trained to administer epinephrine, a role some may view as overlapping with EMS or medical personnel, though the bill itself presents this as a supplemental emergency response measure.